Novo Nordisk A/S NONOF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 51.46B | 50.94B | 46.79B | 46.70B | 45.46B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 51.46B | 50.94B | 46.79B | 46.70B | 45.46B |
| Cost of Revenue | 9.27B | 8.56B | 8.25B | 7.76B | 7.16B |
| Gross Profit | 42.19B | 42.38B | 38.54B | 38.93B | 38.30B |
| SG&A Expenses | 9.75B | 10.08B | 10.28B | 10.51B | 10.48B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 40.39M | 7.47M | -11.10M | 35.54M | 50.42M |
| Total Operating Expenses | 26.22B | 25.81B | 25.52B | 24.17B | 23.16B |
| Operating Income | 25.23B | 25.13B | 21.26B | 22.53B | 22.30B |
| Income Before Tax | 23.24B | 24.20B | 19.69B | 19.44B | 20.51B |
| Income Tax Expenses | 5.05B | 5.24B | 4.24B | 4.15B | 4.33B |
| Earnings from Continuing Operations | 18.20K | 18.96K | 15.45K | 15.30K | 16.18K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.20B | 18.96B | 15.45B | 15.30B | 16.18B |
| EBIT | 25.23B | 25.13B | 21.26B | 22.53B | 22.30B |
| EBITDA | 27.07B | 26.97B | 23.09B | 24.22B | 23.78B |
| EPS Basic | 4.10 | 4.27 | 3.48 | 3.44 | 3.64 |
| Normalized Basic EPS | 3.70 | 3.69 | 3.06 | 3.16 | 3.10 |
| EPS Diluted | 4.09 | 4.26 | 3.47 | 3.44 | 3.64 |
| Normalized Diluted EPS | 3.69 | 3.69 | 3.05 | 3.15 | 3.09 |
| Average Basic Shares Outstanding | 17.76B | 17.78B | 17.77B | 17.78B | 17.78B |
| Average Diluted Shares Outstanding | 17.78B | 17.79B | 17.79B | 17.80B | 17.81B |
| Dividend Per Share | 1.82 | 1.81 | 1.81 | 1.70 | 1.70 |
| Payout Ratio | 44.74% | 42.93% | 49.09% | 49.60% | 44.93% |